Tag: cytotoxic payloads
Lonza Opens News Facility for ADC Payload Manufacturing Following a Tailored...
Lonza, a specialty Contract Development and Manufacturing partner for biopharmaceutical companies, inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload)...
ADCs – Look Forward to a Potent Future
Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In...
PharmaMar and Seattle Genetics Sign Licensing Agreement for Fully Synthetic Marine-derived...
Earlier this week PharmaMar, an Madrid-based biopharmaceutical company developing innovative marine-derived anticancer drugs, signed an exclusive agreement with Seattle Genetics in which the company...
Q&A – an Interview with Lonza’s Laurent Ducry
Antibody-drug Conjugates or ADCs are among the most exciting drug developments of the last decade. The combination of potent, small molecule drugs with the...
Validating Meditope Biosciences’ Unique SnAP Technology Platform
Data presented in an abstract at the annual meeting of the American Association for Cancer Research (AACR), taking place April 18-22, 2015 in Philadelphia,...
